Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-04-18
2006-04-18
Weddington, Kevin E. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S179000
Reexamination Certificate
active
07030132
ABSTRACT:
A method for increasing the systemic exposure of cells selected from tumor cells and normal cells to an orally administered pharmaceutically active compound, wherein a bioenhancer comprising an inhibitor of BCRP is orally administered concomitantly with said orally administered pharmaceutically active compound, and in which method the inhibitor is administered simultaneously with the pharmaceutical compound.
REFERENCES:
patent: 5567592 (1996-10-01), Benet et al.
patent: 5604237 (1997-02-01), Dumaitre et al.
patent: 5663179 (1997-09-01), Dumaitre et al.
patent: 5786344 (1998-07-01), Ratain et al.
patent: 5958937 (1999-09-01), Hausheer et al.
patent: 6004927 (1999-12-01), Benet et al.
patent: 6028054 (2000-02-01), Benet et al.
patent: 6248891 (2001-06-01), Sharp et al.
patent: 6469022 (2002-10-01), Schellens
patent: 6521635 (2003-02-01), Bates et al.
patent: 0 098 098 (1984-01-01), None
patent: 0 494 623 (1992-07-01), None
patent: WO 92/12132 (1992-07-01), None
patent: WO 94/01408 (1994-01-01), None
patent: WO 96/11007 (1996-04-01), None
patent: WO 97/15269 (1997-05-01), None
patent: WO 98/53811 (1998-12-01), None
patent: WO 99/40110 (1999-08-01), None
patent: WO 99/65493 (1999-12-01), None
patent: WO 00/07605 (2000-02-01), None
Rabindran et al., Cancer Research, 58, 5850-5858, Dec. 15, 1998.
Hazlehurst et al., Cancer Research, 59, 1021-1028, Mar. 1, 1999.
B. Kuska, Journal of the National Cancer Institute, vol. 91, No. 5, 402-404, Mar. 3, 1999.
Ross et al., Journal of the National Cancer Institute, vol. 91, No. 5, 429-433, Mar. 3, 1999.
K. Miyake et al., Cancer Research, Jan. 1, 1999, vol. 59, pp. 8-13.
Allikmets et al., Cancer Research, 58, 5337-5339, Dec. 1, 1998.
Doyle et al., Proc. Natl. Acad. Sci. USA, vol. 95, pp. 15665-15670, Dec. 1998.
Palmer et al., J. Med. Chem. 1988, 31, 707-712.
Denny et al., J. Med. Chem. 1987, 30, 658-663.
Sparreboom et al., Anticancer Drugs, 10(8): 719-728, Sep. 1999.
de Bruin et al., Cancer Letters, 146 (1999) 117-126.
Hyafil et al., Cancer Research, 53, 4595-4602, Oct. 1, 1993.
Karato et al., Journal of Clinical Oncology, vol. 11, No. 10, pp. 2030-2035, Oct. 1993.
Slichenmyer et al., J. Natl. Cancer Inst., vol. 85, No. 4, pp. 271-291, 1993.
Sikic et al., 12thBristol Myers Squibb Nagoya International Cancer Treatment Symposium, Oct. 4-5, 1996, Nagoya, Japan, pp. S13-S19.
Sparreboom et al., Proc. Natl. Acad. Sci. USA, vol. 94, 2031-2035, Mar. 1997.
Rabindran et al., Proceedings of the American Association for Cancer Research-Annual Meeting, Mar. 1999, vol. 40, pp. 315-316, Abstract #2093.
International Search Report.
Rabindran, S.K., “Fumitremorgin C reverses a novel multidrug resistance mechanism in mitoxantrone-selected cells”, Wyeth-Ayerst Research, XP-000878953.
Rabindran, S.K., “Reversal of a Novel Multidrug Resistance Mechanism in Human Colon Carcinama Cells by Fumitremorgin”, Cancer Research 585850-5858, Dec. 15, 1998, XP-000876633.
Hazlehurst, L.A., “Multiple Mechanism Confer Drug Resistance to Mitoxantrone in the Human 8226 Myeloma Cell Line”, Cancer Research 59, 1021-1028, Mar. 1, 1999, XP-000876632.
Scheffer et al., Cancer Research 60, 2589-2593, May 15, 2000.
Maliepaard et al., Cancer Research 59, 4559-4563, Sep. 15, 1999.
Allen et al., Cancer Research 59, 4237-4241, Sep. 1, 1999.
Rabindran et al., Cancer Research 60, 47-50, Jan. 1, 2000.
M. Brangi et al., Cancer Research 59, 5938-5946, Dec. 1, 1999.
M.D. DeMario et al., Journal of Clinical Oncology, vol. 16, No. 7, Jul. 1998, pp. 2557-2567.
Schellens Johannes Henricus Matthias
Schinkel Alfred Hermanus
Birch & Stewart Kolasch & Birch, LLP
Cancer Research Ventures Limited
Weddington Kevin E.
LandOfFree
Method of improving bioavailability of orally administered... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of improving bioavailability of orally administered..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of improving bioavailability of orally administered... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3601855